JPMorgan Chase & Co. Purchases 18,472 Shares of ProKidney Corp. (NASDAQ:PROK)

JPMorgan Chase & Co. raised its position in ProKidney Corp. (NASDAQ:PROK) by 65.1% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 46,830 shares of the company’s stock after buying an additional 18,472 shares during the period. JPMorgan Chase & Co.’s holdings in ProKidney were worth $90,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of PROK. Charles Schwab Investment Management Inc. boosted its position in shares of ProKidney by 150.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company’s stock worth $1,439,000 after purchasing an additional 450,548 shares during the last quarter. Suvretta Capital Management LLC boosted its position in shares of ProKidney by 32.1% in the 3rd quarter. Suvretta Capital Management LLC now owns 12,341,266 shares of the company’s stock worth $23,695,000 after purchasing an additional 3,000,000 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of ProKidney by 102.0% in the 3rd quarter. Geode Capital Management LLC now owns 2,203,934 shares of the company’s stock worth $4,232,000 after purchasing an additional 1,112,933 shares during the last quarter. State Street Corp boosted its position in shares of ProKidney by 16.2% in the 3rd quarter. State Street Corp now owns 1,428,318 shares of the company’s stock worth $2,742,000 after purchasing an additional 198,836 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of ProKidney by 575.7% in the 3rd quarter. Barclays PLC now owns 146,321 shares of the company’s stock worth $281,000 after purchasing an additional 124,667 shares during the last quarter. 51.59% of the stock is currently owned by institutional investors.

ProKidney Stock Down 1.2 %

NASDAQ:PROK opened at $1.65 on Monday. The stock’s fifty day simple moving average is $1.77 and its 200-day simple moving average is $1.95. The firm has a market capitalization of $481.24 million, a P/E ratio of -3.00 and a beta of 1.32. ProKidney Corp. has a 12-month low of $1.18 and a 12-month high of $4.44.

ProKidney (NASDAQ:PROK) last posted its earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). As a group, equities research analysts expect that ProKidney Corp. will post -0.57 earnings per share for the current year.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.